Teva has made its second state-level opioid settlement in as many weeks, having reached an agreement with the attorney general of Florida that settles the claims of the state and its subdivisions against the pharmaceutical firm.
Teva Settles Opioid Litigation In Florida For $177m
Firm Will Also Provide State With $84m Worth Of Generic Narcan
Teva has settled the opioid claims it faced in the state of Florida, alongside CVS, Allergan and Endo.
More from Legal & IP
More from Generics Bulletin
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.